lieparm inhibits endothelm-1 production in cultured rat mesangial cells. The present study was designed to examine whether hepann inhibits basal or stimulated endothelin-l production by arginine vasopressin (AVP) and platelet-derived growth factor (PDGF) in cultured rat mesangial cells. In addition, the reversibility of the heparin effect on mesangial cell endothelin-l production was examined. AVP and PDGF stimulated endothelin-l secretion in a concentration-dependent manner in these cells. Heparin (10 to 100 U/mI) exhibited concentration-related inhibition of AVP-and PDGF-stimulated endothelin-l secretion. Heparm also had weak but significant inhibitory effects on basal endothelin-1 secretion in these cells. The protein kinase (PKC)-activating phorbor ester, phorbor myristate acetate (PMA), stimulated endothelinl secretion and heparin inhibited PMA-stimulated endothelin-1 secretion. In addition, the inhibitory effect of heparin was completely abolished in PKC-depleted mesangial cells. Mesangial cells which were exposed to a high concentration (100 U/mI) of heparin for 24 hours were capable of producing endothelin-1 alter a short lag period of removal of heparin from the culture medium. These mesangial cells also showed recovery of responses to AVP and PDGF by secreting a significantly greater amount of endothelin-l than the non-stimulated level. These results indicate that heparin potently inhibits mesangial cell endothelin-l production, especially when stimulated by AVP or PDGF. This inhibitory effect of heparin is probably PKC dependent, and reversible. Endothelin-1 exerts a potent vasoconstrictive effect on a variety of blood vessels including renal artery [10] [11] [12] . This peptide is also shown to bind to its specific receptors and induce the contraction and proliferation of glomerular mesangial cells [3, 13] . Endothelin has been reported to play a role in variety of diseases that affect the kidney, including severe hypertension [14-161, acute renal failure [17-19] and cyclosporine nephrotox-
mesangial cells. In addition, the reversibility of the heparin effect on mesangial cell endothelin-l production was examined. AVP and PDGF stimulated endothelin-l secretion in a concentration-dependent manner in these cells. Heparin (10 to 100 U/mI) exhibited concentration-related inhibition of AVP-and PDGF-stimulated endothelin-l secretion. Heparm also had weak but significant inhibitory effects on basal endothelin-1 secretion in these cells. The protein kinase (PKC)-activating phorbor ester, phorbor myristate acetate (PMA), stimulated endothelinl secretion and heparin inhibited PMA-stimulated endothelin-1 secretion. In addition, the inhibitory effect of heparin was completely abolished in PKC-depleted mesangial cells. Mesangial cells which were exposed to a high concentration (100 U/mI) of heparin for 24 hours were capable of producing endothelin-1 alter a short lag period of removal of heparin from the culture medium. These mesangial cells also showed recovery of responses to AVP and PDGF by secreting a significantly greater amount of endothelin-l than the non-stimulated level. These results indicate that heparin potently inhibits mesangial cell endothelin-l production, especially when stimulated by AVP or PDGF. This inhibitory effect of heparin is probably PKC dependent, and reversible.
Glomerular mesangial cells are directly related to glomerular function through their contractility and proliferation. These cells have receptors specific to various vasoactive peptides and growth factors such as arginine vasopressin (AVP) [1, 2] , endothelin [3, 4] and platelet-derived growth factor (PDGF) [5, 6] . Recent evidence indicates that AVP and PDGF bind to their specific receptors, and induce the contraction and proliferation of mesangial cells [1, [7] [8] [9] .
Endothelin-1 exerts a potent vasoconstrictive effect on a variety of blood vessels including renal artery [10] [11] [12] . This peptide is also shown to bind to its specific receptors and induce the contraction and proliferation of glomerular mesangial cells [3, 13] . Endothelin has been reported to play a role in variety of diseases that affect the kidney, including severe hypertension , acute renal failure [17] [18] [19] and cyclosporine nephrotoxReceived for publication April 1, 1993 and in revised form August 3, 1993 Accepted for publication August 8, 1993 © 1994 by the International Society of Nephrology icity [20, 21] . In fact, we have previously shown that plasma endothelin-1 levels are significantly increased in hypertensive patients with impaired renal function and in severe hypertensive rats with renal damage [14, 15] . Furthermore, recent studies demonstrated constitutive expression of endothelin-1 transcripts and peptide secretion in cultured rat mesangial cells [22, 23] . This endothelin-l production by mesangial cells is found to be stimulated by AVP and PDGF [2, 24, 25] . These observations have led to the possibility that endothelin-1 may play a role as a modulator of renal function. On the other hand, recently we [26] have shown that heparin treatment reduces vascular endothelial cell production of endothelin-1 and lowers blood pressure in spontaneously hypertensive rats (SHR). Therefore, if heparin inhibits mesangial cell production of endothelin-1, heparin treatment may modulate renal function in certain pathological states, including hypertension and glomerular diseases.
Accordingly, the present study was designed to test the two hypotheses: (1) that heparin inhibits basal endothelin-1 secretion in cultured rat mesangial cells; and (2) that heparin inhibits AVP-and PDGF-stimulated endothelin-l secretion in these cells. In addition, we examined whether this inhibitory effect of heparin on mesangial cells was reversible. were purchased from Becton Dickinson and Co. (Oxnard, California, USA). Endothelin-1, endothelin-2, endothelin-3, and big endothelin-1 (porcine, 1-39) were purchased from under sterile conditions as previously reported [23] . The isolated glomeruli were then cultured in RPM! 1640 medium containing 20% FCS and antibiotics. The identity of the mesangial cells was confirmed by the following criteria: (1) morphology; (2) typical microfilaments seen by transmission electron microscopy; (3) survival in a medium containing D-valine substituted for L-valine, indicating the existence of D-amino acid oxidase; (4) resistance to puromycin aminonucleoside (10 g!ml) but susceptibility to mitomycin C (10 jg/ml); (5) presence of receptors specific to Ang II and contraction in response to Ang II; and (6) absence of immunofluorescence with factor VIII antibody. The cultures were maintained at 37°C with atmospheric air and 5% CO2. and subculture was carried out after treatment with Versene® followed by trypsin. Cells after three to seven passages were used for this experiment.
Pharmacological treatment
The culture medium was removed and the cell monolayers were washed twice with serum-free RPMI-1640. Various concentrations of AVP (10-6 M, lO M and 108 M) or PDGF (50 ng/ml, S ng/ml and 0.5 ng/ml) were added to the individual wells, and the cells were incubated at 37°C for 24 and 48 hours. These concentrations of AVP and PDGF are shown to stimulate mesangial cell production of endothelin-1 in cultured rat or human mesangial cells [24, 25] . In separate experiments, various concentrations of heparin (100 U/mi, 10 U/nil and 1 U/mI) were added in the absence or presence of iO M AVP or 5 ng/ml PDGF, and the cells were incubated at 37°C for 24 hours.
In final experiments, we tested whether mesangial cells which were exposed to a high concentration of heparin (100 U/mi) for 24 hours were capable of producing endothelin-1 after a short lag period of removal of heparin. The heparin-containing medium was removed and replaced with medium plus 0.5% FCS or medium plus 0.5% FCS and iO-M AVP or 5 ng/ml PDGF. Accumulated endothelin-1 levels at 0 to 24 hours, at 24 to 48 hours, and at 48 to 72 hours after the removal of heparin were measured.
All experiments were performed with 2 ml of RPMI-1640 under quiescent (0.5% FCS) conditions. After the incubation, the medium was aspirated and centrifuged at 3000 x g for 10 minutes, and the supernatant was collected and stored at -80°C until radioimmunoassay.
Measurement of endothelin-1 concentration
Immunoreactive (ir)-endothelin-1 was extracted as previously described [27] . Briefly, 1.5 ml of each sample was diluted with 4 ml of 4% acetic acid. After centrifugation, the solution was pumped at the rate of 1 mI/mm through a Sep-Pak C18 cartridge (Millipore Corp., Milford, Massachusetts, USA). Mter evaporation of the elute with 86% ethanol in 4% acetic acid by centrifugal evaporator (Model RD-3 1, Yamato Scientific Co., Tokyo, Japan), the dry residue was dissolved in the assay buffer described below. The recovery rate was found by adding three different quantities of cold endothelin-1 (10, 50 and 100 pg/mi) to serum-free RPM! 1640. Recovery was 69 2%.
The ir-endothelin-1 concentration was assayed using endothelin-1 antiserum and '251-endothelin-l as a tracer. This antibody reacts 100% with endothelin-l and cross reacts 7% with endothelin-2, 7% with endothelin-3 and 35% with big endothelin-1(porcine, 1-39). The antiserum did not cross react with bovine serum albumin, 0.1% Nonidet P-40 and 0.0 1% NaN3, as previously described [28] . In brief, rehydrated antiserum (100 ILl) was added to 100 l of the sample or 100 jd of standard endothelin-l dissolved in the assay buffer and the mixture was incubated for 24 hours at 4°C. Approximately 15,000 cpm of '251-endothelin-1 was added to each reaction and incubated for an additional 24 hours. After this incubation, 100 tl of diluted normal rabbit serum and 100 d of diluted goat anti-rabbit immunoglobin 0 were added and the mixture was again incubated for 24 hours. After the third incubation, the precipitate was collected by centrifugation at 1700 g for 30 minutes. The supernatant was removed by aspiration and the pellet was counted for 125! with a gamma counter. The level of detectable ability of this assay was 0.2 pg/mi with a range of 0.2 to 200 pg/ml. The interassay variation was 13% and the intra-assay variation was 7%. AVP, PDGF and heparin did not interfere with the radioimmunoassay.
Calculations and statistical analysis The statistical significance of differences in the results were evaluated by analysis of variance, and P values were calculated by Scheffe's method [29] . Values are expressed as mean SD.
Results
Effects of AVP and PDGF on mesangial cell endothelin-1 secretion AVP and PDGF increased ir-endothelin-1 secretion in a time-dependent fashion. These stimulatory effect were clearly concentration-dependent (Table 1) .
Effects of heparin on basal and stimulated mesangial cell endothelin-1 secretion + Significant difference compared with values when AVP only was added (P < 0.05). Each point is the mean of six measurements.
affect basal ir-endothelin-1 secretion (5.2 1.0 pg/mi) compared to control (5.4 0.9 pg/mi). However, in higher doses (10 and 100 U/mi) heparin showed weak but significant inhibitory effects (10 U/mi, 4.0 0.6 pg/mi; 100 U/mi, 3.4 0.7 pg/mi). Figure 2 shows effect of heparin on AVP-stimulated irendothelin-1 secretion from cultured mesangial cells. Heparin in small dose (1 U/mi) did not affect ir-endothelin-1 secretion (13.0 1.4 pg/mi), whereas 10 and 100 U/mi heparin exhibited concentration-related inhibition (10 U/mi, 10.5 1.2 pg/mi; 100 U/mi, 7.6 0.9 pg/mi) of AVP-stimulated ir-endothelin-1 secretion (15.5 1.7 pg/mi). However, even in a highest dose (100 U/mi) heparin could not inhibit the secretion to the control level (7.6 0.9 pg/mi vs. 5.4 0.8 pg/mI). Figure 3 shows effect of heparin on PDGF-stimulated irendothelin-l secretion from cultured mesangial cells. Heparin in small dose (1 U/mi) did not affect ir-endothelin-1 secretion (21.6 2.5 pg/mi), whereas 10 and 100 U/mi heparin exhibited concentration-related inhibition (10 U/mi, 17.3 2.3 pg/mi; 100 U/mi, 12.7 1.5 pg/mi) of PDGF-stimulated ir-endothelin-l secretion (24.3 3.0 pg/mi). However, even in a highest dose Reversibility of the inhibitory effect of heparin on endothelin-1 secretion Next, we tested whether the inhibitory effects of heparin on mesangial cell ir-endothelin-1 secretion was reversible. At 24 hours after exposure to high concentration (100 U/mi) of heparin, the heparin-containing medium was removed and replaced with medium plus 0.5% FCS or medium plus 0.5% FCS and l0 M AVP or S ng/ml PDGF. Accumulated endothelin-1 levels at 0 to 24 hours, at 24 to 48 hours, and at 48 to 72 hours after the removal of heparin were 3.8 0.5 pg/mi, 4.8 0.6 pg/mi, and 5.8 0.9 pg/mi, respectively (Fig. 5) . Mesangial cells which were previously exposed to heparin were capable of producing ir-endothein-l after a short lag period of removal of heparin from the culture medium. These mesangial cells were also capable of responding to AVP and PDGF and of secreting significantly greater amounts of endothelin-1 than non-stimulated levels (AVP 0 to 24 hr, 7. 
pg/mI). ________
To test the hypothesis that heparin inhibits mesangiai cell production of endotheiin-l through the inhibition of PKC, the effect of the PKC-activating phorbor ester, PMA, on ir-endothelin-1 secretion and the effect of heparin on PMA-stimulated ir-endothelin-l secretion were examined. PMA stimulated irendotheiin-1 secretion in a concentration-dependent fashion To confirm the importance of PKC-dependent mechanisms in the inhibition of endothelin-l by heparin, the effect of heparin on ir-endothelin-1 secretion was examined in PKC-depleted mesangiai cells. PKC-depietion was made by preincubation with a high dose of PMA (10 M) for 24 hours. The inhibitory effect of heparin on ir-endotheiin-l secretion was completely abolished in PKC-depleted cells (Table 2) . Discussion In the present study, we have confirmed the previous reports that AVP as well as PDGF stimulates a vasoconstrictive and growth-promoting peptide, endothelin-1, in cultured rat mesangial cells [2, 24, 25] and we have presented data for the first time that heparin inhibits AVP-and PDGF-stimulated endothelin-1 secretion in these cells. We also have shown that heparin was weak but significant inhibitory effects on basal endothelin-1 Reversibility of the heparin effect on mesangial cell endotheun-I production. Heparin-containing medium was replaced with medium alone or medium plus i0M AVP or 5 ng/ml PDGF. Accumulated endothelin-1 levels at 0 to 24 hours, at 24 to 48 hours, and at 48 to 72 hours after the removal of heparin were shown. * Significant difference compared with control level (with 0.5% FCS only) (P < 0.05). Each point is the mean of six measurements.
secretion in cultured rat mesangial cells. The present results are in agreement with our recent report [26] that heparin inhibits endothelin-1 secretion in cultured rat aortic endothelial cells.
Next, we showed that the PKC-activating phorbor ester, PMA, stimulated endothelin-1 secretion and heparin clearly inhibited PMA-stimulated endothelin-l secretion. Actually, a high dose (100 U/mi) of heparin completely suppressed PMAstimulated endothelin-1 secretion. However, this suppressive effect of heparin was abolished in PKC-depleted mesangial cells. Therefore, our findings suggest that heparin suppresses mesangial cell production of endothelin-1 probably through a mechanism of inhibition of PKC. Although PKC-depletion prevented the heparin-induced fall in endotheiin-1 production, the baseline levels with PKC-depletion were similar to the heparin-induced fall. One possible explanation is that the basal endothelin-l production is also PKC-dependent and heparin inhibits the basal endothelin-l production as well as AVP-and PDGF-stimulated production most likely through a common mechanism of inhibition of PKC. We speculate that even in [35] have demonstrated that heparin inhibits mesangial cell proliferation. In the present study, we showed that heparin inhibits basal and AVP-or PDGF-stimulated mesangial cell production of endothelin-1. Taken together, these findings indicate that endothelin-1 has vasoconstrictive effect on renal vasculature and some mitogenic activities for glomerular mesangial cells. Thus heparin treatment by its inhibitory effects on production of endothelin-1 in vascular endothelial and mesangial cells, as well as by its anticoagulation and antimitogenic action, may help to attenuate hypertension and glomerular dysfunction.
Finally, we showed that mesangial cells which were exposed to a high concentration of heparin for 24 hours were capable of secreting endothelin-l. These mesangial cells also were capable of responding to AVP and PDGF and of secreting greater amount of endothelin-1 than non-stimulated level. These results suggest that the inhibitory effect of heparin on mesangial cell production of endothelin-1 is reversible and not simply a function of killing mesangial cells. Actually, heparin-containing medium in our experiment did not contain detached cells.
Overall, our data indicate that heparin inhibits mesangial cell endothelin-1 secretion probably through the inhibition of PKC and this effect is reversible. Therefore, heparin treatment may modulate glomerular hemodynamics in part through the inhibition of mesangial endothelin-1 production, especially when endogenous endothelin-1 production is enhanced by AVP or PDGF. If so, this action may be added to the anticoagulation and antimitogenic action [35] as yet another effect of heparin of benefit in certain pathological states. However, it remains to be clarified whether heparin has a role in modulating endothelin-1 production in glomerular mesangial cells in vivo, since high concentrations of heparin are required to inhibit the AVP or PDGF effect on endothelin-1 production. In addition, further investigation will be necessary to elucidate the exact cellular mechanism by which heparin inhibits mesangial cell endothelin-l production.
